Jump to content
Powered by BIOPRO BW
  • BIOPRO BW
  • Healthcare industry
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
Healthcare industry Logo

Main navigation

  • Start page Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close Close
  • Databases

    Databases

    Close Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Press release - 23/09/2025

    Not all ALK fusions act the same: Variants influence treatment success in lung cancer

    About five percent of lung adenocarcinomas, one of the most common forms of lung cancer, are driven by a faulty fusion of two genes, EML4 and ALK. This fusion results in different variants, and until now, clinicians have treated all patients with these fusions the same way. However, new research led by scientists from the German Cancer Research Center (DKFZ) and Stanford University shows that not all fusion variants behave alike.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/not-all-alk-fusions-act-same-variants-influence-treatment-success-lung-cancer
  • Press release - 16/09/2025

    New CRISPR method leads to a better understanding of cell functions

    The 2020 Nobel Prize in Chemistry was awarded for the development of CRISPR/Cas9, a method also known as “gene scissors”, which enables researchers to better understand how human cells function and stay healthy. Researchers at the University of Stuttgart have further developed CRISPR for this purpose. They present their CRISPRgenee method in Cell Reports Methods.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-crispr-method-leads-better-understanding-cell-functions
  • Press release - 15/09/2025

    How HIV enters the genome – Researchers identify previously unknown mechanism

    Researchers at Heidelberg Uni Hospital have decoded a previously unknown mechanism by which HIV-1 selects its integration targets in the human genome. A research team identified RNA:DNA hybrids as molecular signposts for the virus. These findings reveal a vulnerability in the life cycle of HIV and provide therapeutic approaches for specifically controlling HIV reservoirs in the body. This has been one of the obstacles to curative HIV therapies.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-hiv-enters-genome-researchers-identify-previously-unknown-mechanism
  • Press release - 12/09/2025

    In bad company: Immune cells in the tumor environment determine the success of therapy for childhood brain tumors

    The cellular environment of a tumor can either support or sabotage recovery. The most comprehensive study to date on the tumor microenvironment in low-grade gliomas, conducted by KiTZ, Jena University Hospital, the DKFZ, and Heidelberg University Hospital, shows what a supportive or obstructive “neighborhood” looks like in childhood brain tumors. The study also provides clues as to how tumor communication might be blocked.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/bad-company-immune-cells-tumor-environment-determine-success-therapy-childhood-brain-tumors
  • Press release - 09/09/2025

    Molecular Biomimetics: The Cell Nucleus as a Model for DNA-based Computer Chips

    In the human body, stem cells process genetic information in an exceptionally reliable and very fast manner. To do this, they access certain sections of the DNA in the cell nucleus. Researchers at KIT have investigated how the DNA-based information processing system works. Their results show that this process is comparable to processes in modern computers and could therefore serve as a model for new types of DNA-based computer chips.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/molecular-biomimetics-cell-nucleus-model-dna-based-computer-chips
  • Press release - 04/09/2025

    Rare bone tumors: Tailor-made mini-proteins switch off tumor drivers

    Chordomas are rare bone tumors for which there are no effective drugs. A research team from the DKFZ and the NCT Heidelberg has now developed a promising approach: Tailor-made mini-proteins specifically block the driver of tumor development. In the result, slowing the growth of chordoma cells in the laboratory and in a mouse model, while also revealing further molecular vulnerabilities of the tumor that could be addressed with approved drugs.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/rare-bone-tumors-tailor-made-mini-proteins-switch-tumor-drivers-1
  • Press release - 03/09/2025

    Therapeutic vaccination against HPV-related tumors: Nanoparticles make the difference

    Researchers from the German Cancer Research Center (DKFZ) have collaborated with the SILVACX project group at Heidelberg University to develop a therapeutic vaccination concept that can mobilize the immune system to target cancer cells. The team showed that virus peptides coupled to silica nanoparticles can elicit effective T-cell responses against HPV-related tumors.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/therapeutic-vaccination-against-hpv-related-tumors-nanoparticles-make-difference
  • Press release - 28/08/2025

    Inhibition of cell division induces immunoreactive peptides in cancer cells

    A team of scientists from the German Cancer Research Center (DKFZ) and the Netherlands Cancer Institute has discovered a previously unknown vulnerability in cancer cells: When cell division is blocked with chemotherapeutic agents such as Taxol, cancer cells produce small immunogenic peptides that could open up new avenues for immune-based cancer therapies.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/inhibition-cell-division-induces-immunoreactive-peptides-cancer-cells
  • Press release - 21/08/2025

    Nanodroplets Could Speed Up the Search for New Medicine

    Until now, the early phase of drug discovery for the development of new therapeutics has been cost- and time-intensive. Researchers at KIT have developed a platform on which extremely miniaturized nanodroplets with a volume of 200 nanoliters per droplet and containing 300 cells per test can be arranged. This platform enables the researchers to synthesize and test thousands of therapeutic agents on the same chip, saving time and resources.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/nanodroplets-could-speed-search-new-medicine
  • Press release - 14/08/2025

    Freezing brain tumor cells in a dormant state

    Every brain tumor is made up of cells in successive stages of activation. Researchers have now analyzed the individual structure of these activation pyramids in malignant brain tumors. In doing so, they discovered a signaling protein that slows down the transition from a dormant to an activated state by epigenetically reprogramming the cells. The hope is that this will permanently freeze cancer cells in a dormant state and thus halt tumor growth.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/freezing-brain-tumor-cells-dormant-state
  • Press release - 12/08/2025

    Biomarkers for Brain Insulin Resistance Discovered in the Blood

    If the brain no longer responds properly to insulin (insulin resistance), this can lead to overweight, diabetes, and Alzheimer's disease. Researchers at the DZD in Potsdam and Tübingen have discovered small chemical modifications to genetic material (epigenetic changes*) in the blood that indicate how well the brain responds to insulin. These markers could help to detect insulin resistance in the brain – by means of a simple blood test.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/biomarkers-brain-insulin-resistance-discovered-blood
  • Press release - 05/08/2025

    Playing Dominos: how an artificial protein emerges from fitting together individual components

    The targeted engineering of artificial proteins with unique properties – that is possible with the assistance of a novel method developed by a research team of Heidelberg University. It centers around a new AI model. This allows for forecasting how two proteins have to be fitted together at the molecular level from individual parts – subunits – in order to engineer a functional, adjustable new protein.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/playing-dominos-how-artificial-protein-emerges-fitting-together-individual-components
  • Press release - 04/08/2025

    FOXP1 syndrome: Potential therapeutic approach discovered for rare language development disorder

    FOXP1 syndrome is a congenital disorder in which the brain development of affected children is severely impaired due to a genetic variant. A research team from the Medical Faculty Heidelberg at Heidelberg University has now demonstrated in mice, that the inhibition of a specific enzyme in the brain can improve abnormal behavior and immune cell dysfunction in the brain. The results have been published in the journal Advanced Science.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/foxp1-syndrome-potential-therapeutic-approach-discovered-rare-language-development-disorder
  • Breath test replaces invasive diagnostics - 30/07/2025 Der Sensor auf einer Handfläche, der gerade einmal ein Drittel der des Handtellers bedeckt.

    Novel smartphone sensor offers innovative breath test to detect Helicobacter infection

    The stomach bacterium Helicobacter pylori is widespread and, if left undetected, can impact our well-being and also lead to serious health conditions. While effective treatments exist, a reliable diagnosis is essential. To address this, researchers have developed an affordable breath test that uses a mini-sensor to detect the presence of the bacterium. They are currently working on a smartphone-compatible version for self-testing.

    https://www.gesundheitsindustrie-bw.de/en/article/news/novel-smartphone-sensor-offers-innovative-breath-test-detect-helicobacter-infection
  • Press release - 29/07/2025

    New method to design custom protein binder

    Designing protein binders from scratch has long been a daunting challenge within the field of computational biology. Researchers have now developed an innovative, training-free pipeline that uses the fundamental principle of shape complementarity to design site-specific protein binders, which are then optimised to fit precisely onto chosen target sites. The researchers tested this on proteins linked to cancer.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-method-design-custom-protein-binder
  • Press release - 24/07/2025

    The origin of evil: stem cell-like cells are the reason for relapses of blood cancer in children and adolescents

    Stem cell-like leukemia cells are responsible for relapses in children and adolescents with a certain type of blood cancer, T-ALL. Researchers at the Hopp Children's Cancer Center Heidelberg (KiTZ), the Molecular Medicine Partnership Unit and the German Cancer Research Center were able to show this in a study. The results could help to overcome resistance in this form of blood cancer and prevent relapses.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/origin-evil-stem-cell-cells-are-reason-relapses-blood-cancer-children-and-adolescents
  • Press release - 24/07/2025

    What makes cells migrate – and what can stop them

    Konstanz researchers identify an enzyme that plays a role in the migration of cells in our body - not only during normal tissue formation and wound healing, but also when tumor cells metastasize. This makes the enzyme an interesting candidate for potential future therapeutic approaches.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/what-makes-cells-migrate-and-what-can-stop-them
  • Press release - 22/07/2025

    Colorectal cancer in type 2 diabetes: An insightful look into the microenvironment of tumors

    Diabetics have a higher risk of colorectal cancer and often a poorer prognosis after developing the disease. The biological mechanisms behind this association were largely unknown. A research team at the German Cancer Research Center (DKFZ) has now discovered that tumors with a low number of immune cells appear to be particularly susceptible to the harmful effects of diabetes.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/colorectal-cancer-type-2-diabetes-insightful-look-microenvironment-tumors
  • Press release - 21/07/2025

    Cancer Cachexia: Liver Identified as Driver of Body Wasting

    Many people with cancer experience dramatic loss of muscle and fat tissue. In many cases, even the heart muscle is affected. This wasting syndrome, affects around half of all cancer patients. Researchers from Helmholtz Munich, in collaboration with Heidelberg University Hospital, the Technical University of Munich, and the German Center for Diabetes Research, have now identified a previously overlooked driver of cachexia: the liver.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/cancer-cachexia-liver-identified-driver-body-wasting
  • Press release - 15/07/2025

    Mapping the metabolism of blood stem cells

    Researchers from the Max Planck Institute of Immunobiology and Epigenetics in Freiburg and ETH Zürich have created the first integrated map detailing the metabolic and molecular changes in human blood stem cells as they age, specialize, or turn cancerous. Their innovative research, made possible by highly sensitive low-input techniques, identifies the nutrient choline, as a key player in preserving youthful stem cell traits.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/mapping-metabolism-blood-stem-cells
  • Press release - 15/07/2025

    ERC funding for research into improved cancer immunotherapies

    With its Proof of Concept grants, the European Research Council (ERC) supports scientists in further developing the economic potential of their research results. Two scientists from the German Cancer Research Center (DKFZ) have now received this coveted funding for the second time.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/erc-funding-research-improved-cancer-immunotherapies
  • Press release - 11/07/2025

    Cellular stress response – researchers discover potential therapeutic target for heart failure

    Researchers at the German Centre for Cardiovascular Research (DZHK) have identified a key molecule involved in a form of heart failure that has so far been difficult to treat.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/cellular-stress-response-researchers-discover-potential-therapeutic-target-heart-failure
  • Press release - 08/07/2025

    Five million euros for research into early cancer detection

    Investing in a healthier future: The HORNBACH Group is supporting the new National Cancer Prevention Center in Heidelberg with a donation of five million euros. In the future, a new laboratory will conduct research into more effective early detection and screening methods.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/five-million-euros-research-early-cancer-detection
  • Press release - 04/07/2025

    Breakthrough in Artificial Blood Production

    Scientists have been working on the artificial production of blood for several decades. Making a new discovery, researchers from the Institute for Cellular Biology and Immunology Thurgau at the University of Konstanz, in collaboration with Queen Mary University of London, have come an important step closer to this goal.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/breakthrough-artificial-blood-production
  • Press release - 03/07/2025

    Focus on Muscle Metabolism: Sex Differences in Sport and Obesity

    The skeletal muscles of men and women process glucose and fats in different ways. A study provides the first comprehensive molecular analysis of these differences. The results possibly give an explanation why metabolic diseases such as diabetes manifest differently in women and men – and why they respond differently to physical activity.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/focus-muscle-metabolism-sex-differences-sport-and-obesity
  • Computer tool opens up new ways to address antibiotic resistance - 02/07/2025 Graphic and symbolic explanation of how PhARIS works. Phages are analysed and thus identified.

    PhARIS identifies effective phages against multi-resistant bacteria

    Bacteriophages - viruses that specifically attack and destroy bacteria - are emerging as promising alternatives to antibiotics in the fight against drug-resistant infections. To speed this effort, researchers have created PhARIS, a computational tool that mines genomic data to pinpoint phages that are effective against S. aureus. By rapidly matching phage and pathogen, PhARIS can accelerate the development of targeted phage therapies.

    https://www.gesundheitsindustrie-bw.de/en/article/news/pharis-identifies-effective-phages-against-multi-resistant-bacteria
  • Press release - 16/06/2025

    Novel laboratory models pave the way for targeted therapies for childhood sarcomas

    Sarcomas in soft tissue usually occur in young people and are difficult to treat. Due to a lack of laboratory models, the causes of their development are poorly understood. A team of researchers has now succeeded in creating mouse models with a functioning immune system that replicate sarcoma types that remain unstudied. The method opens up new avenues for the targeted development of immunotherapies for children and adolescents with sarcomas.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/novel-laboratory-models-pave-way-targeted-therapies-childhood-sarcomas
  • Press release - 12/06/2025

    BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer

    Acquisition will strengthen the mRNA-based cancer immunotherapy candidates, marking BioNTech’s milestone in its oncology strategy. Acquisition of CureVac will complement BioNTech’s capabilities and proprietary technologies in mRNA design, delivery formulations, and mRNA manufacturing. All-stock acquisition has potential to create value for both companies’ shareholders given their complementary capabilities, focus on mRNA, and shared vision.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/biontech-announces-strategic-transaction-acquire-curevac-public-exchange-offer
  • Press release - 22/05/2025

    Six Clusters of Excellence for the University of Tübingen

    Tübingen achieves remarkable success and has good chance of maintaining its University of Excellence title – Top research in three areas to be sustained from other sources of support.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/six-clusters-excellence-university-tubingen
  • Press release - 21/05/2025

    How aging changes the blood system in humans and mice

    The reservoir of blood stem cells shrinks with age. It becomes increasingly dominated by stem cells that produce immune cells associated with chronic inflammation. Almost all of the 60-year-olds studied show this change. The new discovery could help explain the chronic inflammation that occurs with age and makes us more susceptible to disease. It could also help identify early warning signs of unhealthy aging processes.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-aging-changes-blood-system-humans-and-mice
  • Press release - 19/05/2025

    How the Epstein-Barr virus promotes its spread in the body

    Many people are infected with the Epstein-Barr virus (EBV), and most are unaware of it. However, EBV can sometimes cause cancer, and this pathogen also appears to play an important role in multiple sclerosis and other autoimmune diseases. Researchers have discovered that EBV increases the ability of infected immune cells to migrate. In this way, the pathogen promotes its spread in the body – a discovery that may have therapeutic implications.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-epstein-barr-virus-promotes-its-spread-body
  • Press release - 13/05/2025

    Award for Outstanding Contributions to Cancer Research

    Dr Dr Varun Venkataramani and Dr Moritz Mall have been awarded this year’s Hella Bühler Prize for their outstanding research on the interaction between nerve and tumor cells and on tumor plasticity. The award granted by Heidelberg University goes to young researchers from the Heidelberg research location who have already drawn attention to themselves through the outstanding scientific quality of their cancer research.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/award-outstanding-contributions-cancer-research
  • Press release - 08/05/2025

    Childhood brain tumors develop early in highly specialized nerve cells

    Medulloblastomas, childhood brain tumors in children, are thought to develop between the first trimester of pregnancy and the end of the first year of life. Researchers have now published their findings in the journal Nature. They analyzed the genetic changes of each individual cancer cell in tumor samples in order to reconstruct which genetic changes occur first during tumor development and when.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/childhood-brain-tumors-develop-early-highly-specialized-nerve-cells
  • New treatment methods: DNA origami-based nanodevices precisely control immune response - 24/04/2025 Hydroborierung_synthetische-Immunologie.png

    Bottom-up synthetic immunology for novel therapeutic approaches

    Modern therapies for combating cancer and infectious diseases increasingly leverage the body’s own immune system. Several research groups at Heidelberg University are using innovative bottom-up approaches in synthetic immunology to develop new treatment methods that can control the immune response more precisely than previously possible.

    https://www.gesundheitsindustrie-bw.de/en/article/news/bottom-synthetic-immunology-novel-therapeutic-approaches
  • Press release - 16/04/2025

    Hereditary Alzheimer’s: Blood Marker for Defective Neuronal Connections Rises Early

    Individuals with a genetic predisposition to Alzheimer’s disease show altered blood levels indicating damaged neuronal contacts as early as 11 years before the expected onset of dementia symptoms. This is evident in the levels of the protein “beta-synuclein”. An international team report these findings in the journal “Alzheimer’s & Dementia”. The biomarker studied here could potentially help to detect neurodegeneration at an early stage.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/hereditary-alzheimers-blood-marker-defective-neuronal-connections-rises-early
  • Press release - 08/04/2025

    Freiburg cancer researcher receives the German Cancer Award 2025

    Melanie Börries, Professor of Medical Bioinformatics at the Medical Faculty of the University of Freiburg and Director of the Institute of Medical Bioinformatics and Systems Medicine at the Medical Center – University of Freiburg, is being honoured for her pioneering work in personalised cancer therapy.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/freiburg-cancer-researcher-receives-german-cancer-award-2025
  • Press release - 07/04/2025

    Physical training has a positive effect on the sexual health of women with metastatic breast cancer

    Metastatic breast cancer requires complex and lengthy treatment, the side effects of which affect the quality of life of patients. These often include sexual problems. In a large international randomized exercise intervention trial, researchers have now shown that women who received a nine-month supervised exercise program reported significantly fewer symptoms than women who did not participate in the training program.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/physical-training-has-positive-effect-sexual-health-women-metastatic-breast-cancer
  • Press release - 03/04/2025

    Heinz Maier-Leibnitz Prize for Lukas Bunse

    Germany's most important award for young scientists honors the development of immunotherapies against malignant brain tumors.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/heinz-maier-leibnitz-prize-lukas-bunse
  • SpecPlate: an innovative multiwell plate - 26/03/2025 The two founders sitting, looking at the new SpecPlate microtitre plate.

    Focus on innovative drug development - accurate, time- and cost-saving

    Drug research is a complex and costly process that requires extensive laboratory analyses and vast quantities of consumables, with disposable sample carriers in particular being used in their millions. PHABIOC GmbH has come up with a solution in the form of the SpecPlate, a ground-breaking alternative to sample carriers that reduces the time taken to perform analyses as well as the quantity of materials consumed. Serial production is underway.

    https://www.gesundheitsindustrie-bw.de/en/article/news/focus-innovative-drug-development-accurate-time-and-cost-saving
  • Press release - 24/03/2025

    Resistance mechanism in chronic lymphocytic leukemia identified

    Researchers at the German Cancer Research Center (DKFZ) have succeeded in identifying a resistance mechanism that often occurs in a specific targeted therapy against chronic lymphocytic leukemia (CLL). The drug ibrutinib is effective in many cases, but therapy resistance often develops during the course of treatment. In cell culture experiments and in mice, the resistance mechanism was successfully overcome using a second drug.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/resistance-mechanism-chronic-lymphocytic-leukemia-identified
  • Press release - 19/03/2025

    Pocket-sized breath test for stomach bacteria Mini sensor analyses breath for infection with Helicobacter pylori

    Stomach ulcers, gastritis and even stomach cancer are often the result of an infection with Helicobacter pylori. If the bacterium remains unrecognised for a long time, this can have serious consequences. Researchers have now developed a miniaturisable sensor system for the mobile analysis of breath that is effective, fast and inexpensive. The research team uses a biological survival trick of the stomach germ to detect the bacterium.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/pocket-sized-breath-test-stomach-bacteria-mini-sensor-analyses-breath-infection-helicobacter-pylori
  • Press release - 17/03/2025

    New approach for T-cell immunotherapy against malignant brain tumors

    Researchers have developed a promising cellular immunotherapy for the treatment of glioblastomas: They equipped T cells with a receptor that recognizes a protein of the brain tumors that is responsible for the dangerous stem cell properties. The therapeutic T cells directed against this target structure were able to specifically destroy human brain tumors in laboratory experiments and in mice.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-approach-t-cell-immunotherapy-against-malignant-brain-tumors
  • Press release - 14/03/2025

    Tool identifies specific viruses to combat dangerous bacteria

    University of Tübingen research team shortens the search for attackers that can wipe out multiresistant pathogens – with the aim of treating infections without antibiotics

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/tool-identifies-specific-viruses-combat-dangerous-bacteria
  • Press release - 12/03/2025

    Hepatic stellate cells control liver function and regeneration

    Until now, doctors knew hepatic stellate cells mainly as drivers of liver fibrosis. The actual functions have hardly been studied to date. Researchers from the German Cancer Research Center, the Mannheim Medical Faculty and Columbia University have now published that hepatic stellate cells control liver metabolism as well as liver regeneration and size. The results of the study could contribute to new therapeutic approaches for liver diseases.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/hepatic-stellate-cells-control-liver-function-and-regeneration
  • Press release - 06/03/2025

    NMI TT in Reutlingen and Düsseldorf University Women's Hospital develop high-precision method for analyzing individual circulating tumor cells

    Researchers have developed a new method that enables a more precise analysis of individual tumor cells circulating in the blood. This allows not only the previously possible genomic investigation of such tumor cells, but also the focused analysis of single-cell signaling pathways at the functional protein level. The combined analysis of the mutated genome and signaling proteins opens up new avenues for more targeted treatment methods.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/nmi-tt-reutlingen-and-duesseldorf-university-womens-hospital-develop-high-precision-method-analyzing-individual-circulating-tumo
  • Press release - 06/03/2025

    New insights into the cellular mechanism of action of psilocybin

    A recent study by the Hector Institute for Translational Brain Research at the CIMH provides the first cellular insights into how psilocin promotes the growth and networking of human nerve cells.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-insights-cellular-mechanism-action-psilocybin
  • Press release - 05/03/2025

    Frank Winkler receives the Brain Prize 2025

    This year, the Brain Prize worth more than one million euros, honors pioneering work on nervous system-cancer interactions: Neurologist Frank Winkler, who researches at the Heidelberg University and at the German Cancer Research Center and treats patients with brain tumors at the Heidelberg University Hospital, discovered that nerve cells in the brain communicate with brain tumor cells. This causes the disease to progress.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/frank-winkler-receives-brain-prize-2025
  • Press release - 28/02/2025

    Early Excellence in Science Award für Ivana Winkler

    The Bayer Foundation's Early Excellence in Science Award 2024 in the category of Data Science goes to Ivana Winkler of the German Cancer Research Center (DKFZ). Winkler's work uncovered the unexpected effect of female reproductive capacity: the constantly recurring remodeling of the organs of the female reproductive tract during the sexual cycle leads to fibrosis and chronic inflammation over the years.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/early-excellence-science-award-fuer-ivana-winkler
  • Press release - 13/02/2025

    Guardian molecule keeps cells on track – new perspectives for the treatment of liver cancer

    A guardian molecule ensures that liver cells do not lose their identity. The discovery is of great importance for cancer medicine because a change of identity of cells has come into focus as a fundamental principle of carcinogenesis for several years. The research team was able to show that the newly discovered guardian is so powerful that it can slow down highly potent cancer drivers and cause malignant liver tumors to regress in mice.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/guardian-molecule-keeps-cells-track-new-perspectives-treatment-liver-cancer
  • Press release - 12/02/2025

    Therapeutic Designer Peptide to Combat Acute Heart Muscle Weakness

    Researchers of the Heidelberg University, Heidelberg University Hospital (UKHD) and Heidelberg Institute for Theoretical Studies (HITS) have developed a synthetic peptide based on the natural protein S100A1, a nearly universal “fuel” for weakened hearts. The researchers combined computer-aided methods with lab studies to investigate the therapeutic effect of the so called S100A1ct peptide molecule.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/therapeutic-designer-peptide-combat-acute-heart-muscle-weakness

Page 2 / 7

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
  • Portals
    • BIOPRO BW
    • Healthcare industry
  • To top

stay informed

Newsletter abonnieren

Social Media

  • Xing Xing
  • Twitter visit Twitter
  • LinkedIn visit LinkedIn
  • Rss visit RSS
  • Privacy statement
  • Accessability Declaration
  • Legal notice
  • Sitemap
  • Contact
© 2026
Website address: https://www.gesundheitsindustrie-bw.de/en/search